Xu Chao Zhang

List of Publications by Year in Descending Order

55 papers	1,241 citations	17 h-index	34 g-index
64 ext. papers	1,674 ext. citations	5.8 avg, IF	3.85 L-index

#	Paper	IF	Citations
55	Real-World Survival Outcomes Based on Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.. *JTO Clinical and Research Reports*, **2022**, 3, 100257	1.4	2
54	Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.. *Cancer Discovery*, **2022**, OF1-OF12	24.4	2
53	Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. *Nature Communications*, **2021**, 12, 6450	17.4	9
52	MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. *Experimental Hematology and Oncology*, **2021**, 10, 52	7.8	2
51	Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer. *Molecular and Clinical Oncology*, **2021**, 14, 36	1.6	2
50	Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. *European Journal of Cancer*, **2021**, 150, 23-30	7.5	4
49	Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer. *Clinical and Experimental Metastasis*, **2021**, 38, 109-117	4.7	10
48	Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). *Clinical Lung Cancer*, **2021**, 22, 100-109.e3	4.9	7
47	Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. *Cancer Treatment and Research Communications*, **2021**, 26, 100297	2	1
46	High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer. *Thoracic Cancer*, **2021**, 12, 2564-2573	3.2	3
45	Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells. *Oncogene*, **2021**, 40, 1476-1489	8.2	7
44	TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer.. *Frontiers in Oncology*, **2021**, 11, 740427	5.3	0
43	Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism. *Clinical and Translational Medicine*, **2020**, 10, 337-345	5.7	3
42	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. *Biomarker Research*, **2020**, 8, 19	8	17
41	Clinical characteristics and prognostic value of the mutation in Chinese non-small cell lung cancer patients. *Biomarker Research*, **2020**, 8, 22	8	14
40	Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma. *Thoracic Cancer*, **2020**, 11, 346-352	3.2	7
39	Establishment and application of a method of next generation sequencing of 285 genes in lung cancer based on Ion-Proton platform.. *Translational Cancer Research*, **2020**, 9, 4239-4249	0.3	

38	Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report. *Thoracic Cancer*, **2020**, 11, 2717-2722	3.2	6
37	Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. *Journal of Thoracic Disease*, **2020**, 12, 5822-5832	2.6	1
36	Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases. *JAMA Network Open*, **2020**, 3, e209077	10.4	2
35	Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1 CD8 and CD8 T cells as predictive of response to neoadjuvant chemotherapy in breast cancer. *Thoracic Cancer*, **2020**, 11, 2941-2954	3.2	3
34	Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. *Thoracic Cancer*, **2020**, 11, 1512-1521	3.2	14
33	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. *Journal of Clinical Oncology*, **2019**, 37, 2235-2245	2.2	94
32	A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. *Lung Cancer*, **2019**, 131, 134-138	5.9	7
31	Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. *Journal of Hematology and Oncology*, **2019**, 12, 18	22.4	46
30	DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. *OncoImmunology*, **2019**, 8, e1509173	7.2	14
29	Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. *Thoracic Cancer*, **2018**, 9, 1093-1103	3.2	11
28	Identification of leptomeningeal metastasis-specific exosomal miRNA signature in cerebrospinal fluid of non-small-cell lung cancer patients.. *Journal of Clinical Oncology*, **2018**, 36, e21024-e21024	2.2	1
27	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. *Cancer Immunology, Immunotherapy*, **2018**, 67, 471-481	7.4	4
26	Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. *Journal of Thoracic Oncology*, **2018**, 13, 1668-1675	8.9	63
25	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. *Lung Cancer*, **2018**, 125, 86-92	5.9	31
24	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. *MAbs*, **2018**, 10, 1301-1311	6.6	37
23	PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. *OncoImmunology*, **2017**, 6, e1284722	7.2	58
22	Acquired Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2017**, 23, 4929-4937	12.9	50
21	Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells. *Clinical Cancer Research*, **2017**, 23, 5480-5488	12.9	52

20	Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. *Journal of Hematology and Oncology*, **2017**, 10, 68	22.4	43
19	Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. *Lung Cancer*, **2017**, 114, 90-95	5.9	15
18	Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer. *Clinical Lung Cancer*, **2017**, 18, 85-91	4.9	9
17	Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer. *Chinese Medical Journal*, **2017**, 130, 1446-1453	2.9	1
16	CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression. *Frontiers in Immunology*, **2017**, 8, 1713	8.4	4
15	Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform. *Cancer Biology and Medicine*, **2016**, 13, 68-76	5.2	4
14	Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation.. *Journal of Clinical Oncology*, **2016**, 34, 9054-9054	2.2	0
13	Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinoma. *Oncology Letters*, **2016**, 11, 213-223	2.6	7
12	Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299. *Asia-Pacific Journal of Clinical Oncology*, **2016**, 12, 41-51	1.9	4
11	Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. *Cancer Prevention Research*, **2015**, 8, 165-73	3.2	88
10	Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing. *Journal of Genetics and Genomics*, **2015**, 42, 579-587	4	3
9	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. *International Journal of Cancer*, **2015**, 137, 311-9	7.5	55
8	Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis. *Journal of Thoracic Disease*, **2015**, 7, 1205-12	2.6	6
7	The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma. *Journal of Thoracic Disease*, **2015**, 7, 1630-6	2.6	10
6	Lung cancer treatment disparities in China: a question in need of an answer. *Oncologist*, **2014**, 19, 1084-90	5.7	17
5	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. *PLoS ONE*, **2012**, 7, e40109	3.7	136
4	A prospective phase II study of induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer.. *Journal of Clinical Oncology*, **2012**, 30, 7039-7039	2.2	1
3	In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. *Cancer Chemotherapy and Pharmacology*, **2011**, 67, 637-46	3.5	48

2	Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. *Journal of Hematology and Oncology*, **2011**, 4, 5	22.4	22
1	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. *Journal of Clinical Oncology*, **2011**, 29, 3316-21	2.2	184